

12 December 2023

Treatment of Colorectal Cancer

In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.

Metastatic and Non-metastatic patient data is not held.

Regimens	Total patients
Capecitabine	5
CAPIRI	<5
CAPOX	<5
Cetuximab with FOLFIRI	10
Cetuximab with FOLFOX	<5
Cetuximab as a single agent	<5
Cetuximab with Encorafenib	<5
Irinotecan as a single agent	<5
FOLFIRI (is this also known as IMDG – IMDG figure given)	9
FOLFOX	15
Fluorouracil (5FU) as a single agent	<5
Oxaliplatin as a single agent	<5
Nivolumab with Ipilimumab	<5
Panitumumab with FOLFIRI	<5
Panitumumab with FOLFOX	<5
Panitumumab as a single agent	<5
Pembrolizumab	<5
Any other systemic anti-cancer therapy	Bevacizumab+Folfiri - <5, Capecitabine+Oxaliplatin-34 Capecitabine XRT- <5 Irinotecan+Capecitabine-<5 Regorafenib - <5
Palliative care only	Not recorded

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.